Wang MT, et al. - An inquiry was set up in order to inspect the risk of cardiovascular disease (CVD) associated with long-acting β₂-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs), emphasizing on the initiation and duration of LABA and LAMA therapies in patients with chronic obstructive pulmonary disease (COPD). Regardless of prior CVD status and history of exacerbations, the new initiation of LABAs or LAMAs in patients with COPD was related to an approximate 1.5-fold increased severe cardiovascular risk.